Late-stage ovarian cancer patients responded well to an experimental carboplatin/decitabine combination therapy, even though they had become resistant to carboplatin, Indiana University researchers report. Furthermore, the researchers believe they have discovered biomarkers that could assist in identifying patients who are most likely to benefit from this therapy.
The carboplatin/decitabine drug combination produced a positive result in 70% of patients in this phase 2 trial. The combination was tolerated well and did not produce any dose-limiting toxicities. In 12 of 17 carboplatin-resistant patients whose cancer was progressing, tumor growth slowed considerably or stopped altogether patients following treatment with the experimental drug combination. Moreover, 1 woman’s tumor became undetectable; however, at 336 days her cancer progression resumed. At 6 months, 9 women were still in remission.